- Home
- FRBA vs RCKT Comparison
FRBA vs RCKT Comparison
Compare FRBA & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRBA | RCKT |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | 336 | 202 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.6M | 401.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FRBA | RCKT |
|---|---|---|
| Price | $18.24 | $3.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $17.50 | ★ $29.73 |
| AVG Volume (30 Days) | 111.1K | ★ 3.1M |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.68 | N/A |
| Revenue Next Year | $6.08 | $64.28 |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.41 | $2.53 |
| 52 Week High | $18.19 | $5.45 |
Technical Indicators
Market Signals| Indicator | FRBA | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 67.82 | 47.70 |
| Support Level | $14.71 | $3.36 |
| Resistance Level | N/A | $3.56 |
| Average True Range (ATR) | 0.47 | 0.25 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 89.82 | 30.28 |
Price Performance
Historical ComparisonAbout FRBA First Bank
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of business. Its services are Business Banking, Personal Banking, Digital Banking, and Lending.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.